Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep917 | Thyroid | ECE2020

Total thyroidectomy for amiodarone-induced thyrotoxicosis: Identification of the surgical candidates and preparation to surgery

Cappellani Daniele , Papini Piermarco , Maria Di Certo Agostino , Mantuano Michele , Manetti Luca , Materazzi Gabriele , Bartalena Luigi , Bogazzi Fausto

Background: Amiodarone-induced thyrotoxicosis (AIT) is a challenging disease associated with increased morbidity and mortality. The European Thyroid Association guidelines define the role for total thyroidectomy in the management of AIT. However, these recommendations were based on small series, which often lead to heterogeneous results and, importantly, did not identify patients who may benefit from surgery.Materials and methods: Observational longitudi...

ea0092ps3-29-06 | Treatment 2 | ETA2023

Dabrafenib and trametinib treatment in patients with braf-mutated advanced thyroid cancer

Contartese Lea , Prete Alessandro , Gambale Carla , Torregrossa Liborio , Papini Piermarco , De Napoli Luigi , Minaldi Elisa , Materazzi Gabriele , Molinaro Eleonora , Elisei Rossella , Matrone Antonio

Introduction: The combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) was approved by the Food and Drug Administration in USA as first line treatment for BRAF-positive anaplastic thyroid cancer. Moreover, it was also available as second line treatment in BRAF-positive advanced thyroid cancers, previously treated with other systemic treatments.Purpose: We evaluated the efficacy and safety of the combination therapy with dabrafenib an...